Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Accelerating Vaccine Development: Applications to COVID-19 and Future Pandemics

The COVID-19 pandemic has created an urgent need to develop a safe and effective vaccine. Currently, research groups around the world are working to develop more than 90 investigational vaccine candidates. While several vaccine candidates are already being tested in clinical trials, there are still critical unanswered questions around the expected clinical effectiveness of immunization. How long will protection last? What inoculation dose and regimen is needed? Which vaccine platform will provide optimal comparative effectiveness (classical strategies of weakened viral particles or components versus the various RNA and DNA vaccine strategies)?

Speaker(s): Thomas Kerbusch,Amy Cheung,Jos Lommerse,Piet van der Graaf
More Info

HIV Déjà Vu? Optimizing Cocktail Therapies for COVID-19

With a vaccine likely a year or longer away, there is urgency around determining the right therapeutic at the right dose to fight COVID-19. Results from clinical trials of monotherapies have been a mixed bag to date, and there has not been a clear leading and proven therapeutic in this race. Monotherapy treatment must be initiated very early in viral infection and be quite potent. A combination therapy where different steps of the SARS-CoV-2 life cycle are modestly impacted may be a better strategy. A cocktail of antiviral drugs or a mix of antivirals and anti-inflammatory medicines could be more effective against COVID-19 than monotherapies, which is what we learned with HIV. We propose that combinations of drugs that act at multiple sites in the viral life cycle should be evaluated in randomized controlled clinical trials.

Speaker(s): Rajesh Krishna,Edward Mills,Michael Dodds,Suzanne Minton
Solution: PK/PD Modeling & Simulation
Therapeutic Area: Infectious Disease
More Info

Considerations for Management of Clinical Trials and Regulatory Filing Strategy in Light of COVID-19

COVID-19 has the potential to negatively impact critical activities such as patient recruitment, patient safety and ensuring data integrity. Thus, clinical developers should review their planned regulatory filing strategies to determine if modifications are required. Attend this webinar to learn mitigation strategies and best practices that you can begin implementing now.

Speaker(s): Demetrius Carter, Elaine B. Taylor
More Info

What’s New in the Simcyp Simulator v19?

This webinar explained how the latest updates in the Simcyp Simulator v19, Certara’s physiologically-based pharmacokinetic (PBPK) modeling and simulation platform, will support developing safer, more effective medications faster.

Speaker(s): Peter Kilford, Janak Wedagedera, Mian Zhang
Solution: PBPK Modeling & Simulation
More Info



Powered by Translations.com GlobalLink OneLink Software